7 results match your criteria: "User-Centered Design[Affiliation]"
What Do Adolescents and Their Parents Need From Mental Health Integration in Primary Care? A Qualitative Exploration of Design Insights.
J Pediatr Health Care
August 2022
Assistant Investigator, Kaiser Permanente Washington Health Research Institute, and Department of Health Systems and Population Health, University of Washington, Seattle, WA.
Introduction: The design of integrated adolescent mental health care should address needs and preferences of patients and parents/guardians.
Method: We conducted interviews and focus groups with adolescents aged 13-17 years who received care at Kaiser Permanente Washington in 2020 and interviews with parents of such adolescents. We sought to (1) understand the challenges of primary care-based mental health and substance use screening and care for adolescents and (2) identify program design solutions.
Supportive Accountability and Mobile App Use in a Tobacco Control Intervention Targeting Low-Income Minority Mothers Who Smoke: Observational Study.
JMIR Mhealth Uhealth
July 2021
User Centered Design Inc, Ashburn, VA, United States.
Background: Smartphone mobile apps are frequently used in standalone or multimodal smoking cessation interventions. However, factors that impede or improve app usage are poorly understood.
Objective: This study used the supportive accountability model to investigate factors that influence app usage in the context of a trial designed to reduce maternal smoking in low-income and predominantly minority communities.
Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN).
Clin Cancer Res
December 2019
National Cancer Institute, Bethesda, Maryland.
Article Synopsis
- - The National Cancer Institute revamped its early-phase drug development program in 2014, creating the Experimental Therapeutics Clinical Trials Network (ETCTN) to support collaboration across over 40 academic institutions for cancer research focused on tumors with specific molecular profiles.
- - The ETCTN has achieved significant milestones, including the submission of 334 letters of intent, activation of 102 clinical trials, and enrollment of 3,570 patients, highlighting the effectiveness of team science and mentorship for emerging researchers.
- - Future directions for the ETCTN emphasize continued collaboration, the importance of senior investigator involvement, and investment in infrastructure to enhance research and precision medicine in cancer trials, demonstrating the program's potential for impactful drug development.
Technology Applications: Use of Digital Health Technology to Enable Drug Development.
JCO Clin Cancer Inform
December 2018
Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom.
Purpose: This pilot study developed and evaluated the feasibility, usability, and perceived satisfaction with an end-user mobile medical application and provider web portal. The two interfaces allowed for remote monitoring, provided daily guidance in the management of hypertension and diarrhea, and allowed for rapid management of adverse events during a clinical trial of olaparib and cediranib.
Patients And Methods: eCO (eCediranib/Olaparib) was designed for patient self-reported, real-time management of hypertension and diarrhea using remote monitoring.
Effects of personalized colorectal cancer risk information on laypersons' interest in colorectal cancer screening: The importance of individual differences.
Patient Educ Couns
October 2015
Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Objective: To evaluate how personalized quantitative colorectal cancer (CRC) risk information affects laypersons' interest in CRC screening, and to explore factors influencing these effects.
Methods: An online pre-post experiment was conducted in which a convenience sample (N=578) of laypersons, aged >50, were provided quantitative personalized estimates of lifetime CRC risk, calculated by the National Cancer Institute Colorectal Cancer Risk Assessment Tool (CCRAT). Self-reported interest in CRC screening was measured immediately before and after CCRAT use; sociodemographic characteristics and prior CRC screening history were also assessed.
AccrualNet: Addressing Low Accrual Via a Knowledge-Based, Community of Practice Platform.
J Oncol Pract
November 2011
National Cancer Institute, Bethesda, MD; Center for Social Marketing and Communications Center, FHI360, Washington, DC; Health Communication Consultant, Annapolis, MD; Whitney Interactive Design, High Bridge, NJ; User-Centered Design, Ashburn, VA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Purpose: Present the design and initial evaluation of a unique, Web-enabled platform for the development of a community of practice around issues of oncology clinical trial accrual.
Methods: The National Cancer Institute (NCI) conducted research with oncology professionals to identify unmet clinical trial accrual needs in the field. In response, a comprehensive platform for accrual resources, AccrualNet, was created by using an agile development process, storyboarding, and user testing.
Communication of uncertainty regarding individualized cancer risk estimates: effects and influential factors.
Med Decis Making
June 2011
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland (WMPK, ANF)
Objective: To examine the effects of communicating uncertainty regarding individualized colorectal cancer risk estimates and to identify factors that influence these effects.
Methods: Two Web-based experiments were conducted, in which adults aged 40 years and older were provided with hypothetical individualized colorectal cancer risk estimates differing in the extent and representation of expressed uncertainty. The uncertainty consisted of imprecision (otherwise known as "ambiguity") of the risk estimates and was communicated using different representations of confidence intervals.